This site is intended for Healthcare Professionals only


Brought to you by

Allergies, such as hayfever, can have a profound impact on sufferers’ quality of life. Update your knowledge on allergic rhinitis and understand the role Allevia (fexofenadine 120mg) can play in its management with this range of learning resources.

Supporting customers with hayfever & allergy

Update your knowledge and refresh your recommendations to help customers tackle troublesome allergic rhinitis symptoms

5 min video

An expert’s opinion of fexofenadine 120mg tablets

Dr. Glenis Scadding explains who OTC fexofenadine can be recommended for

2 min video

Understand Allevia’s safety profile

Discover more about Allevia so you can reassure customers about its safety profile and efficacy

2 min video

Click here for essential information and adverse event reporting

Content developed by Sanofi working with CIG Healthcare Partnership.
© 2024 CIG Healthcare Partnership

MAT-XU-2400547 (V1.0)
February 2024


Product information

Allevia 120 mg tablets

Presentation: Allevia (fexofenadine hydrochloride) 120mg film-coated tablets, containing equivalent to 112mg of fexofenadine.Indications: Relief of symptoms associated with allergic rhinitis in adults and children 12 years and older. Dose and administration: Adults and Children ≥ 12 years: The recommended dose is one tablet (120mg) once daily taken before a meal. Children (<12 years old): Allevia should not be used in children under 12 years of age. Elderly; Renally or hepatically impaired patients: studies indicate that dose adjustment is not necessary, but Allevia should only be administered with care in these patients on the advice of a doctor.Contraindications: Hypersensitivity to the active substance or to any of the excipients. Warnings and precautions: Patients with a history of or ongoing cardiovascular disease should be warned that antihistamines as a medicine class have been associated with adverse reactions such as tachycardia and palpitations, and should use Allevia 120 mg only on the advice of their doctor. Interactions: Fexofenadine is a P-glycoprotein (P-gp) and organic-anion-transporting polypeptide (OATP) substrate. Concomitant use of fexofenadine with P-gp inhibitors or inducers can affect the exposure to fexofenadine. Coadministration of fexofenadine hydrochloride with P-gp inhibitors, erythromycin or ketoconazole has been found to increase the level of fexofenadine in plasma. The changes were not accompanied by any effects on the QT interval or an increase in adverse reactions compared to the medicinal products given singly. A clinical drug-drug interaction study showed that co-administration of apalutamide (a weak inducer of P-gp) and a single oral dose of 30 mg fexofenadine resulted in a 30 % decrease in AUC of fexofenadine. It is advisable to leave 2 hours between administration of fexofenadine hydrochloride and aluminium and magnesium hydroxide containing antacids. Pregnancy: Allevia should not be used during pregnancy unless on the advice of a doctor. Lactation: Allevia 120 mg is not recommended for mothers breast-feeding their babies. Breast-feeding women should only use Allevia 120 mg if advised to do so by a doctor. Adverse Reactions: The following undesirable effects have been reported in clinical trials, with an incidence similar to that observed with placebo. Common (≥1/100 and <1/10): Headache, drowsiness, dizziness, nausea. Uncommon (≥1/1,000 and <1/100): Fatigue. The following undesirable effects have been reported in post-marketing surveillance. Frequency not known: Hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnoea, flushing and systemic anaphylaxis, insomnia, nervousness, sleep disorders or nightmares/excessive dreaming (paroniria), tachycardia, palpitations, diarrhoea, rash, urticaria, pruritus, vision blurred. RRP (ex VAT): 30 tablets pack: £8.74, 15 tablets pack: £4.91, 7 tablets pack: £2.91. Legal category: GSL. Product Licence Number: PL 53886/0065. Product licence holder: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK.
Further information is available from Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT.
Email: Document number: MAT-GB-2300132 (v1.0) Date of preparation: June 2023.

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to the Sanofi drug safety department on 0800 0902314